Chronic myeloid leukemia: current status and controversies

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) treatment historically relied on interferon-alfa or allogeneic stem cell transplantation.
• Allogeneic stem cell transplantation, while curative, carries significant risks of morbidity and mortality.
• The BCR-ABL fusion gene's p210 oncoprotein was identified as a key driver in CML pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of imatinib mesylate, a novel tyrosine kinase inhibitor, in treating chronic myeloid leukemia (CML).
• To assess the impact of imatinib on patients with newly diagnosed, accelerated, and blastic phase CML.
• To determine if imatinib necessitates a reevaluation of standard CML management protocols.

Main Methods:

• Clinical trials involving imatinib mesylate in patients with CML.
• Assessment of treatment response, including cytogenetic and durable responses.
• Evaluation of imatinib's activity across different phases of CML.

Main Results:

• Imatinib mesylate demonstrated impressive results in previously untreated patients with CML in chronic phase, with complete cytogenetic response rates exceeding 80%.
• Responses to imatinib in chronic phase CML were largely durable.
• Imatinib showed activity in accelerated and blastic phase CML, though benefits were often short-lived.

Conclusions:

• Imatinib mesylate represents a paradigm shift in the initial management of chronic myeloid leukemia.
• The drug's high efficacy and durable responses in chronic phase CML warrant its consideration as a standard treatment.
• Further reappraisal of CML treatment strategies is needed in light of imatinib's success.